

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Casirivimab and imdevimab**

**INITIATION – Treatment of profoundly immunocompromised patients**

Re-assessment required after 2 weeks

**Prerequisites** (tick boxes where appropriate)

- Patient has confirmed (or probable) COVID-19
- and  The patient is in the community (treated as an outpatient) with mild to moderate disease severity\*
- and  Patient is profoundly immunocompromised\*\* and is at risk of not having mounted an adequate response to vaccination against COVID-19 or is unvaccinated
- and  Patient's symptoms started within the last 10 days
- and  Patient is not receiving high flow oxygen or assisted/mechanical ventilation
- and  Casirivimab and imdevimab is to be administered at a maximum dose of no greater than 2,400 mg

Note: \* Mild to moderate disease severity as described on the [Ministry of Health Website](#)

\*\* Examples include B-cell depletive illnesses or patients receiving treatment that is B-Cell depleting.

**INITIATION – mild to moderate COVID-19-hospitalised patients**

Re-assessment required after 2 weeks

**Prerequisites** (tick boxes where appropriate)

- Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the DHB Hospital.
- and  Patient has confirmed (or probable) COVID-19
- and  Patient is an in-patient in hospital with mild to moderate disease severity\*
- and  Patient's symptoms started within the last 10 days
- and  Patient is not receiving high flow oxygen or assisted/mechanical ventilation
- and  Age > 50
- or  BMI > 30
- or  Patient is Māori or Pacific ethnicity
- or  Patient is at increased risk of severe illness from COVID-19, excluding pregnancy, as described on the Ministry of Health website (see Notes)
- and  Patient is unvaccinated
- or  Patient is seronegative where serology testing is readily available or strongly suspected to be seronegative where serology testing is not available
- and  Casirivimab and imdevimab is to be administered at a maximum dose of no greater than 2,400 mg

Note: \* Mild to moderate disease severity as described on the [Ministry of Health Website](#)

\*\* (<https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-information-specific-audiences/covid-19-advice-higher-risk-people>)

I confirm that the above details are correct:

Signed: ..... Date: .....